Biotech Values

[DewDiligence]

FierceBiotech’s list of top biotech “surprises” for 2013 includes FDA approval of MNTA’s generic Copaxone:

http://www.fiercebiotech.com/press-releases/biotechnology-industry-outlook-top-10-potential-surprises-2013

I don’t consider generic-Copaxone approval especially unlikely, although the market evidently does.

There is, however, one item on FierceBiotech’s 2013 list that I think is almost impossible: GILD making more profit than AMGN.